NEW YORK (GenomeWeb) – Medikonia said today it has inked a distribution agreement to make Amoy Diagnostics' range of molecular diagnostic tests available in Hong Kong and Macau.

Additional terms of the agreement were not disclosed.

Pau Huang, AmoyDx's international sales and marketing director, said in a statement that the firm's molecular diagnostic tests, which are powered by its proprietary PCR-based ADx Amplification Refractory Mutation System (ADx-ARMS) and Super-ARMS technologies, help patients receive the correct cancer drugs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.